Overview

Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to gain initial clinical experience regarding the safety and efficacy of treating type I diabetes in people who have received a kidney transplant by transplanting islets into a new transplant site in the stomach (gastrointestinal submucosa). A total of 6 patients will be enrolled in the study and followed for a period of up to 3 years after the last islet transplant.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Pancreatin
Pancrelipase